Behçet-Syndrom

Zusammenfassung

Das Behçet-Syndrom gehört zu den Vaskulitiden variabler Gefäßgröße. Das klinische Bild ist sehr vielfältig und erfordert in der Regel eine interdisziplinäre Zusammenarbeit. Pathogenetisch scheint es eine Mittelstellung zwischen einer polygenetischen Autoinflammationserkrankung und einer autoimmunen Erkrankung einzunehmen. 2018 wurden neue EULAR-Empfehlungen herausgegeben. Die Therapie richtet sich nach der führenden Beteiligung der einzelnen Organe. Seit 2016 ist Adalimumab zugelassen für die Behandlung der hinteren Augenbeteiligung. Infliximab, Interferon a2a, Interleukin-1-Antagonisten und Apremilast können Therapiealternativen darstellen.

Abstract

Behçet’s syndrome (BS) is classified as a variable vessel vasculitis. The clinical picture is very diverse and usually requires interdisciplinary collaboration. Pathogenetically, BS seems to take a middle position between a polygenic autoinflammatory disease and an autoimmune disease. New EULAR recommendations were issued in 2018. The therapy depends on which organs are most affected. Since 2016, adalimumab has been approved for the treatment of posterior ocular involvement. Infliximab, interferon a2a, interleukin-1 antagonists and apremilast may be alternative therapies.

Schlüsselwörter

Vaskulitis - Review - Therapie - Behçet-Syndrom

Key words

vasculitis - review - therapy - Behçet’s syndrome

• Literatur

• 1 Jennette JC, Falk RJ, Andrassy K. et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-192
• 2 Zouboulis CC, Kaklamanis P. Early descriptions of Adamantiades-Behcet’s disease. Ann Rheum Dis 2003; 62: 691-692
• 3 Behcet H, Matteson EL. On relapsing, aphthous ulcers of the mouth, eye and genitalia caused by a virus. 1937. Clin Exp Rheumatol 2010; 28: S2-S5
• 4 Yazici H, Ugurlu S, Seyahi E. Behcet syndrome: is it one condition?. Clin Rev Allergy Immunol 2012; 43: 275-280
• 5 Hatemi G, Christensen R, Bang D. et al. 2018 update of the EULAR recommendations for the management of Behcet’s syndrome. Ann Rheum Dis 2018; 77: 808-818
• 6 Zouboulis CC, Kotter I, Djawari D. et al. Epidemiological features of Adamantiades-Behcet’s disease in Germany and in Europe. Yonsei Med J 1997; 38: 411-422
• 7 Azizlerli G, Kose AA, Sarica R. et al. Prevalence of Behcet’s disease in Istanbul, Turkey. Int J Dermatol 2003; 42: 803-806
• 8 Yurdakul S, Gunaydin I, Tuzun Y. et al. The prevalence of Behcet’s syndrome in a rural area in northern Turkey. J Rheumatol 1988; 15: 820-822
• 9 Adeeb F, Stack AG, Fraser AD. New insights into Behcet’s disease in Ireland: the Midwest cohort study. Clin Exp Rheumatol 2018; 36: 33-39
• 10 Lin YH, Tai TY, Pu CY. et al. Epidemiology of Behcet’s Disease in Taiwan: A Population-Based Study. Ophthalmic Epidemiol 2018; 25: 323-329
• 11 Zhang Z, He F, Shi Y. Behcet’s disease seen in China: analysis of 334 cases. Rheumatol Int 2013; 33: 645-648
• 12 Giza M, Koftori D, Chen L. et al. Is Behcet’s disease a’ class 1-opathy’? The role of HLA-B * 51 in the pathogenesis of Behcet’s disease. Clin Exp Immunol 2018; 191: 11-18
• 13 de Menthon M, Lavalley MP, Maldini C. et al. HLA-B51/B5 and the risk of Behcet’s disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum 2009; 61: 1287-1296
• 14 Verity DH, Marr JE, Ohno S. et al. Behcet’s disease, the Silk Road and HLA-B51: historical and geographical perspectives. Tissue Antigens 1999; 54: 213-220
• 15 Gul A, Inanc M, Ocal L. et al. Familial aggregation of Behcet’s disease in Turkey. Ann Rheum Dis 2000; 59: 622-625
• 16 Ombrello MJ, Kirino Y, de Bakker PI. et al. Behcet disease-associated MHC class I residues implicate antigen binding and regulation of cell-mediated cytotoxicity. Proc Natl Acad Sci U S A 2014; 111: 8867-8872
• 17 Kirino Y, Bertsias G, Ishigatsubo Y. et al. Genome-wide association analysis identifies new susceptibility loci for Behcet’s disease and epistasis between HLA-B * 51 and ERAP1. Nat Genet 2013; 45: 202-207
• 18 Coit P, Mumcu G, Ture-Ozdemir F. et al. Sequencing of 16S rRNA reveals a distinct salivary microbiome signature in Behcet’s disease. Clin Immunol 2016; 169: 28-35
• 19 Shimizu J, Takai K, Fujiwara N. et al. Excessive CD4 + T cells co-expressing interleukin-17 and interferon-gamma in patients with Behcet’s disease. Clin Exp Immunol 2012; 168: 68-74
• 20 Hamzaoui K, Bouali E, Ghorbel I. et al. Expression of Th-17 and RORgammat mRNA in Behcet’s Disease. Med Sci Monit 2011; 17: CR227-CR234
• 21 Chi W, Zhou S, Yang P. et al. CD4(+) T cells from behcet patients produce high levels of IL-17. Eye Sci 2011; 26: 65-69
• 22 Zeidan MJ, Saadoun D, Garrido M. et al. Behcet’s disease physiopathology: a contemporary review. Auto Immun Highlights 2016; 7: 4
• 23 Wallace GR. HLA-B * 51 the primary risk in Behcet disease. Proc Natl Acad Sci U S A 2014; 111: 8706-8707
• 24 Vaiopoulos G, Konstantopoulou P, Evangelatos N. et al. The spectrum of mucocutaneous manifestations in Adamantiades-Behcet’s disease in Greece. J Eur Acad Dermatol Venereol 2010; 24: 434-438
• 25 Kone-Paut I, Yurdakul S, Bahabri SA. et al. Clinical features of Behcet’s disease in children: an international collaborative study of 86 cases. J Pediatr 1998; 132: 721-725
• 26 Davatchi F, Shahram F, Shams H. et al. Gender influence on ocular manifestations and their outcome in Behcet’s Disease. A long-term follow-up of up to 20 years. Clin Rheumatol 2011; 30: 541-547
• 27 Alpsoy E, Donmez L, Onder M. et al. Clinical features and natural course of Behcet’s disease in 661 cases: a multicentre study. Br J Dermatol 2007; 157: 901-906
• 28 Messadi DV, Younai F. Aphthous ulcers. Dermatol Ther 2010; 23: 281-290
• 29 Bang D, Yoon KH, Chung HG. et al. Epidemiological and clinical features of Behcet’s disease in Korea. Yonsei Med J 1997; 38: 428-436
• 30 Yurdakul S, Yazici H. Behcet’s syndrome. Best Pract Res Clin Rheumatol 2008; 22: 793-809
• 31 Yazici H, Tuzun Y, Pazarli H. et al. Influence of age of onset and patient’s sex on the prevalence and severity of manifestations of Behcet’s syndrome. Ann Rheum Dis 1984; 43: 783-789
• 32 [Anonym]. Criteria for diagnosis of Behcet’s disease. International Study Group for Behcet’s Disease. Lancet 1990; 335: 1078-1080
• 33 Kim B, LeBoit PE. Histopathologic features of erythema nodosum – like lesions in Behcet disease: a comparison with erythema nodosum focusing on the role of vasculitis. Am J Dermatopathol 2000; 22: 379-390
• 34 Wollina U. Pyoderma gangrenosum – a review. Orphanet J Rare Dis 2007; 2: 19
• 35 Keogan MT. Clinical Immunology Review Series: an approach to the patient with recurrent orogenital ulceration, including Behcet’s syndrome. Clin Exp Immunol 2009; 156: 1-11
• 36 Requena L, Yus ES. Panniculitis Part I Mostly septal panniculitis. J Am Acad Dermatol 2001; 45: 163-183 . quiz 184–166
• 37 Tuzun Y, Yazici H, Pazarli H. et al. The usefulness of the nonspecific skin hyperreactivity (the pathergy test) in Behcet’s disease in Turkey. Acta Derm Venereol 1979; 59: 77-79
• 38 Gurler A, Boyvat A, Tursen U. Clinical manifestations of Behcet’s disease: an analysis of 2147 patients. Yonsei Med J 1997; 38: 423-427
• 39 Bonfioli AA, Orefice F. Behcet’s disease. Semin Ophthalmol 2005; 20: 199-206
• 40 Deuter CM, Kotter I, Wallace GR. et al. Behcet’s disease: ocular effects and treatment. Prog Retin Eye Res 2008; 27: 111-136
• 41 Kitaichi N, Miyazaki A, Iwata D. et al. Ocular features of Behcet’s disease: an international collaborative study. Br J Ophthalmol 2007; 91: 1579-1582
• 42 Tugal-Tutkun I, Onal S, Altan-Yaycioglu R. et al. Uveitis in Behcet disease: an analysis of 880 patients. Am J Ophthalmol 2004; 138: 373-380
• 43 Deuter CM, Kotter I, Gunaydin I. et al. Ocular involvement in Behcet’s disease: first 5-year-results for visual development after treatment with interferon alfa-2a. Ophthalmologe 2004; 101: 129-134
• 44 Saadoun D, Cassoux N, Wechsler B. et al. Ocular manifestations of Behcet’s disease. Rev Med Interne 2010; 31: 545-550
• 45 Sakane T, Takeno M, Suzuki N. et al. Behcet’s disease. N Engl J Med 1999; 341: 1284-1291
• 46 Yurdakul S, Yazici H, Tuzun Y. et al. The arthritis of Behcet’s disease: a prospective study. Ann Rheum Dis 1983; 42: 505-515
• 47 Ait Badi MA, Zyani M, Kaddouri S. et al. Skeletal manifestations in Behcet’s disease. A report of 79 cases. Rev Med Interne 2008; 29: 277-282
• 48 Siva A, Kantarci OH, Saip S. et al. Behcet’s disease: diagnostic and prognostic aspects of neurological involvement. J Neurol 2001; 248: 95-103
• 49 Akman-Demir G, Serdaroglu P, Tasci B. Clinical patterns of neurological involvement in Behcet’s disease: evaluation of 200 patients. The Neuro-Behcet Study Group. Brain 1999; 122 (11) 2171-2182
• 50 Siva A, Altintas A, Saip S. Behcet’s syndrome and the nervous system. Curr Opin Neurol 2004; 17: 347-357
• 51 Reske D, Petereit HF, Heiss WD. Difficulties in the differentiation of chronic inflammatory diseases of the central nervous system – value of cerebrospinal fluid analysis and immunological abnormalities in the diagnosis. Acta Neurol Scand 2005; 112: 207-213
• 52 Atasoy HT, Tunc TO, Unal AE. et al. Peripheral nervous system involvement in patients with Behcet disease. Neurologist 2007; 13: 225-230
• 53 Davatchi F, Shahram F, Chams-Davatchi C. et al. Behcet’s disease in Iran: analysis of 6500 cases. Int J Rheum Dis 2010; 13: 367-373
• 54 Koc Y, Gullu I, Akpek G. et al. Vascular involvement in Behcet’s disease. J Rheumatol 1992; 19: 402-410
• 55 Calamia KT, Schirmer M, Melikoglu M. Major vessel involvement in Behcet’s disease: an update. Curr Opin Rheumatol 2011; 23: 24-31
• 56 Ahn JK, Lee YS, Jeon CH. et al. Treatment of venous thrombosis associated with Behcet’s disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation. Clin Rheumatol 2008; 27: 201-205
• 57 Seyahi E, Cakmak OS, Tutar B. et al. Clinical and Ultrasonographic Evaluation of Lower-extremity Vein Thrombosis in Behcet Syndrome: An Observational Study. Medicine (Baltimore) 2015; 94: e1899
• 58 Hamuryudan V, Er T, Seyahi E. et al. Pulmonary artery aneurysms in Behcet syndrome. Am J Med 2004; 117: 867-870
• 59 Seyahi E, Melikoglu M, Akman C. et al. Pulmonary artery involvement and associated lung disease in Behcet disease: a series of 47 patients. Medicine (Baltimore) 2012; 91: 35-48
• 60 Davatchi F, Shahram F, Chams-Davatchi C. et al. Behcet’s disease: from East to West. Clin Rheumatol 2010; 29: 823-833
• 61 Nishiyama M, Nakae K, Yukawa S. et al. A study of comparison between the nationwide epidemiological survey in 1991 and previous surveys on behcet’s disease in Japan. Environ Health Prev Med 1999; 4: 130-134
• 62 Ebert EC. Gastrointestinal manifestations of Behcet’s disease. Dig Dis Sci 2009; 54: 201-207
• 63 Skef W, Hamilton MJ, Arayssi T. Gastrointestinal Behcet’s disease: a review. World J Gastroenterol 2015; 21: 3801-3812
• 64 Vaiopoulos AG, Sfikakis PP, Kanakis MA. et al. Gastrointestinal manifestations of Behcet’s disease: advances in evaluation and management. Clin Exp Rheumatol 2014; 32: S140-S148
• 65 Lee CR, Kim WH, Cho YS. et al. Colonoscopic findings in intestinal Behcet’s disease. Inflamm Bowel Dis 2001; 7: 243-249
• 66 Sands BE. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology 2004; 126: 1518-1532
• 67 Moon CM, Cheon JH, Shin JK. et al. Prediction of free bowel perforation in patients with intestinal Behcet’s disease using clinical and colonoscopic findings. Dig Dis Sci 2010; 55: 2904-2911
• 68 Akpolat T, Akkoyunlu M, Akpolat I. et al. Renal Behcet’s disease: a cumulative analysis. Semin Arthritis Rheum 2002; 31: 317-337
• 69 Alizadeh F, Khorrami MH, Izadpanahi MH. et al. Bladder involvement in Behcet’s disease. Urol J 2012; 9: 347-350
• 70 Kanakis MA, Vaiopoulos AG, Vaiopoulos GA. et al. Epididymo-Orchitis in Bechet’s Disease: A Review of the Wide Spectrum of the Disease. Acta Med Iran 2017; 55: 482-485
• 71 International Team for the Revision of the International Criteria for Behcet’s D. The International Criteria for Behcet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 2014; 28: 338-347
• 72 Sfikakis PP, Theodossiadis PG, Katsiari CG. et al. Effect of infliximab on sight-threatening panuveitis in Behcet’s disease. Lancet 2001; 358: 295-296
• 73 Nguyen QD, Merrill PT, Jaffe GJ. et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet 2016; 388: 1183-1192
• 74 Hamuryudan V, Seyahi E, Ugurlu S. et al. Pulmonary artery involvement in Behcets syndrome: Effects of anti-Tnf treatment. Semin Arthritis Rheum 2015; 45: 369-373
• 75 Tanida S, Inoue N, Kobayashi K. et al. Adalimumab for the treatment of Japanese patients with intestinal Behcet’s disease. Clin Gastroenterol Hepatol 2015; 13: 940-948 e943
• 76 Stadler R, Bratzke B, Baumann I. Behcet disease and exogenous interferon. A successful treatment study using recombinant alpha-A-IFN. Hautarzt 1987; 38: 97-100
• 77 Kotter I, Zierhut M, Eckstein AK. et al. Human recombinant interferon alfa-2a for the treatment of Behcet’s disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003; 87: 423-431
• 78 Albayrak O, Oray M, Can F. et al. Effect of Interferon alfa-2a Treatment on Adaptive and Innate Immune Systems in Patients With Behcet Disease Uveitis. Invest Ophthalmol Vis Sci 2019; 60: 52-63
• 79 Emmi G, Talarico R, Lopalco G. et al. Efficacy and safety profile of anti-interleukin-1 treatment in Behcet’s disease: a multicenter retrospective study. Clin Rheumatol 2016; 35: 1281-1286
• 80 Hatemi G, Melikoglu M, Tunc R. et al. Apremilast for Behcet’s syndrome – a phase 2, placebo-controlled study. N Engl J Med 2015; 372: 1510-1518
• 81 Aktulga E, Altac M, Muftuoglu A. et al. A double blind study of colchicine in Behcet’s disease. Haematologica 1980; 65: 399-402
• 82 Yurdakul S, Mat C, Tuzun Y. et al. A double-blind trial of colchicine in Behcet’s syndrome. Arthritis Rheum 2001; 44: 2686-2692
• 83 Davatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A. et al. Colchicine versus placebo in Behcet’s disease: randomized, doubleblind, controlled crossover trial. Mod Rheumatol 2009; 19: 542-549
• 84 Yazici H, Pazarli H, Barnes CG. et al. A controlled trial of azathioprine in Behcet’s syndrome. N Engl J Med 1990; 322: 281-285
• 85 BenEzra D, Cohen E, Chajek T. et al. Evaluation of conventional therapy versus cyclosporine A in Behcet’s syndrome. Transplant Proc 1988; 20: 136-143
• 86 Masuda K, Nakajima A, Urayama A. et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet’s disease. Lancet 1989; 1: 1093-1096
• 87 Hatemi I, Esatoglu SN, Hatemi G. et al. Characteristics, Treatment, and Long-Term Outcome of Gastrointestinal Involvement in Behcet’s Syndrome: A Strobe-Compliant Observational Study From a Dedicated Multidisciplinary Center. Medicine (Baltimore) 2016; 95: e3348
• 88 Sobaci G, Erdem U, Durukan AH. et al. Safety and effectiveness of interferon alpha-2a in treatment of patients with Behcet’s uveitis refractory to conventional treatments. Ophthalmology 2010; 117: 1430-1435
• 89 Sfikakis PP, Arida A, Panopoulos S. et al. Brief Report: Drug-Free Long-Term Remission in Severe Behcet’s Disease Following Withdrawal of Successful Anti-Tumor Necrosis Factor Treatment. Arthritis Rheumatol 2017; 69: 2380-2385
• 90 Zeydan B, Uygunoglu U, Saip S. et al. Infliximab is a plausible alternative for neurologic complications of Behcet disease. Neurol Neuroimmunol Neuroinflamm 2016; 3: e258
• 91 Bodaghi B, Gendron G, Wechsler B. et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 2007; 91: 335-339